Stay updated with breaking news from Alpine Immune Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- The Company will present updated data in a late-breaking poster session for povetacicept in IgA nephropathy patients -- -- The Company will host an investor event the same day concurrently with...
Oppenheimer restated their outperform rating on shares of Alpine Immune Sciences (NASDAQ:ALPN – Free Report) in a research report report published on Tuesday morning, Benzinga reports. They currently have a $44.00 price target on the biotechnology company’s stock, up from their previous price target of $33.00. Other research analysts have also issued reports about the […]
Wolfe Research started coverage on shares of Alpine Immune Sciences (NASDAQ:ALPN – Free Report) in a report released on Thursday, MarketBeat.com reports. The brokerage issued an outperform rating and a $44.00 target price on the biotechnology company’s stock. Other analysts have also recently issued reports about the stock. Royal Bank of Canada lifted their target […]
Research analysts at Wolfe Research initiated coverage on shares of Alpine Immune Sciences (NASDAQ:ALPN – Get Free Report) in a report released on Thursday, Briefing.com reports. The firm set an “outperform” rating and a $44.00 price target on the biotechnology company’s stock. Wolfe Research’s price target points to a potential upside of 51.05% from the […]
Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report)’s share price traded down 4% during trading on Tuesday . The stock traded as low as $26.34 and last traded at $26.34. 347,216 shares changed hands during trading, a decline of 65% from the average session volume of 991,954 shares. The stock had previously closed at […]